Eugene Laska

Eugene Laska

Auto-generated profile, based on publicly available information

Eugene Laska

Steven and Alexandra Cohen Veterans Center for the Study of Posttraumatic Stress and Traumatic Brain Injury, Department of Psychiatry, New York University School of Medicine

Research Focus & Metrics

Academic Career Length

64Years (1963-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2011 in American Journal of Psychiatry
Verified
Journal Article
Closed access
PDF file
YKYoung Shin Kim
Young Shin Kim
BLBennett L. Leventhal
Bennett L. Leventhal
YKYun-Joo Koh
Yun-Joo Koh
EFEric Fombonne
Eric Fombonne
ELEugene Laska
Eugene Laska
RGRoy Richard Grinker
Roy Richard Grinker

1 June 2001 in The British Journal of Psychiatry
Verified
Journal Article
Open access
PDF file
GHG. Harrison
G. Harrison
KHK. Hopper
K. Hopper
TCT. Craig
T. Craig
ELE. Laska
E. Laska
CSC. Siegel
C. Siegel
DWD. Wiersma
D. Wiersma
Background: Poorly defined cohorts and weak study designs have hampered cross-cultural comparisons of course and outcome in schizophrenia.Aims: To describe long-term outcome in 18 diverse treated incidence and prevalence cohorts. To compare mortality, 15- and 25-year illness trajectory and the predictive strength of selected baseline and short-term course variables.Method: Historic prospective study. Standardised assessments of course and outcome.Results: About 75% traced. About 50% of surviving cases had favourable outcomes, but there was marked heterogeneity across geographic centres. In regression models, early (2-year) course patterns were the strongest predictor of 15-year outcome, but recovery varied by location; 16% of early unremitting cases achieved late-phase recovery.Conclusions: A significant proportion of treated incident cases of schizophrenia achieve favourable long-term outcome. Sociocultural conditions appear to modify long-term course. Early intervention programmes focused on social as well as pharmacological treatments may realise longer-term gains.

1 October 2003 in SLEEP
Verified
Journal Article
Open access
PDF file
AKAndrew D. Krystal
Andrew D. Krystal
JWJames K. Walsh
James K. Walsh
ELEugene Laska
Eugene Laska
JCJudy Caron
Judy Caron
DADavid A. Amato
David A. Amato
TRThomas Roth
Thomas Roth
To determine the long-term efficacy of eszopiclone in patients with chronic insomnia. Randomized, double-blind, multicenter, placebo-controlled. Out-patient, with monthly visits. Aged 21 to 69 years meeting DSM IV criteria for primary insomnia and reporting less than 6.5 hours of sleep per night, and/or a sleep latency of more than 30 minutes each night for at least 1 month before screening. Eszopiclone 3 mg (n = 593) or placebo (n = 195), nightly for 6 months Efficacy was evaluated weekly using an interactive voice-response system. Endpoints included sleep latency; total sleep time; number of awakenings; wake time after sleep onset; quality of sleep; and next-day ratings of ability to function, daytime alertness, and sense of physical well-being. At the first week and each month for the study duration, eszopiclone produced significant and sustained improvements in sleep latency, wake time after sleep onset, number of awakenings, number of nights awakened per week, total sleep time, and quality of sleep compared with placebo (P ≤ 0.003). Monthly ratings of next-day function, alertness, and sense of physical well-being were also significantly better with the use of eszopiclone than with placebo (P ≤ 0.002). There was no evidence of tolerance, and the most common adverse events were unpleasant taste and headache. Throughout 6 months, eszopiclone improved all of the components of insomnia as defined by DSM-IV, including patient ratings of daytime function. This placebo-controlled study of eszopiclone provides compelling evidence that long-term pharmacologic treatment of insomnia is efficacious.

1 May 2008 in Neurobiology of Aging
Verified
Journal Article
Closed access
LMLisa Mosconi
Lisa Mosconi
SSSusan De Santi
Susan De Santi
JLJuan Li
Juan Li
WTWai Hon Tsui
Wai Hon Tsui
YLYi Li
Yi Li
MLMony J. de Leon
Mony J. de Leon

8 November 2006 in Movement Disorders
Verified
Journal Article
Closed access
PDF file
CGChristopher G. Goetz
Christopher G. Goetz
PDPhilippe Damier
Philippe Damier
CHChristine Hicking
Christine Hicking
ELEugene Laska
Eugene Laska
TMThomas Müller
Thomas Müller
HRHermann Russ
Hermann Russ

1 April 2008 in Journal of Clinical Psychopharmacology
Verified
Journal Article
Closed access
JKJohn M. Kane
John M. Kane
JLJohn Lauriello
John Lauriello
ELEugene Laska
Eugene Laska
MMMichael Di Marino
Michael Di Marino
CWCurt D. Wolfgang
Curt D. Wolfgang
This research compared the long-term efficacy and safety of iloperidone with those of haloperidol in individuals with schizophrenia. Data were pooled from 3 prospective multicenter studies, each with 6-week stabilization followed by 46-week double-blind maintenance phases. Patients were randomized to iloperidone 4 to 16 mg/d or haloperidol 5 to 20 mg/d. Patients included in this analysis completed the initial 6-week phase with at least 20% reduction in Positive and Negative Syndrome Scale (PANSS) total score at weeks 4 and 6, had 7-item Clinical Global Impressions of Change (CGI-C) scores less than 4, received 1 or more doses of long-term phase medication, and had 1 or more efficacy/safety assessments during the long-term phase. The primary efficacy variable was time to relapse, defined as a 25% or more increase in PANSS total score, including at least a 10-point change; discontinuation because of lack of efficacy; aggravated psychosis with hospitalization; or 2-point increase in the 7-item CGI-C after week 6. Of 1644 patients randomized and 1326 completing the 6-week phase, 473 (iloperidone, n = 359; haloperidol, n = 114) were included in the long-term efficacy analysis, and 489 (iloperidone, n = 371; haloperidol, n = 118) in the safety analysis. Iloperidone was equivalent to haloperidol in time to relapse. The most common adverse events were insomnia (18.1%), anxiety (10.8%), and schizophrenia aggravated (8.9%) with iloperidone, and insomnia (16.9%), akathisia (14.4%), tremor (12.7%), and muscle rigidity (12.7%) with haloperidol. The Extrapyramidal Symptoms Rating Scale scores improved with iloperidone and worsened with haloperidol. Metabolic changes were minimal for both groups. Mean changes in Fridericia's QT interval correction were 10.3 msec (iloperidone) and 9.4 msec (haloperidol) at end point. Iloperidone demonstrated long-term efficacy equivalent to haloperidol and a favorable long-term safety profile, potentially making this agent a suitable option as maintenance therapy for schizophrenia.